Why the study?
What is the development status of oral, direct Factor Xa inhibitors for the prevention and treatment of thromboembolic diseases?
Population
Patients requiring prevention and treatment of thromboembolic diseases
Design
Review
Authors
Loading...
Oral direct Factor Xa inhibitors represent a promising class of novel anticoagulants in clinical development that may eliminate the need for regular monitoring and dose adjustment.
What is the development status of oral, direct Factor Xa inhibitors for the prevention and treatment of thromboembolic diseases?
Oral direct Factor Xa inhibitors represent a promising class of novel anticoagulants in clinical development that may eliminate the need for regular monitoring and dose adjustment.
Alexander G.G. Turpie (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: